Cited 0 times in
Effects of Pamidronate Treatment on Osteogenesis Imperfecta
|dc.description.abstract||Background:Osteogenesis imperfecta (OI) is a congenital disorder of type I collagen, with variable phenotypes, due to increased bone fragility and low bone mass. Previous pharmacological treatments for OI have been attempted with calcitonin and growth hormone but with little beneficial effects. Recently, Glorieux reported the beneficial effects of bisphosphonates in OI.
Methods:In this study, the effects of pamidronate treatment were evaluated in 9 patients with OI. All patients received intravenous pamidronate infusions, which was dose adjusted according to the patients’ age. The outcome measures included the biochemical bone markers; serum alkaline phosphatase, urine deoxy-pyridinoline, urine Ca/Cr ratio, and bone mineral density (BMD).
Results:Serum alkaline phosphatase, urine deoxypyridinoline, and urine Ca/Cr ratio were slightly decreased after 1 year of therapy, although these changes were not statistically significant. The BMDs of the lumbar spine and proximal femur were significantly increased after 1-year of pamidronate treatment. No fractures were reported during the 1 year treatment periods.
Conclusions:Pamidronate treatment had an effect on the BMD in osteogenesis imperfecta, probably due to decreasing bone resorption
|dc.title||Effects of Pamidronate Treatment on Osteogenesis Imperfecta||-|
|dc.title.alternative||골형성부전증 환자에서 파미드로네이트의 치료 효과||-|
|dc.subject.keyword||Biochemical bone marker||-|
|dc.subject.keyword||Bone mineral density||-|
|dc.citation.title||Journal of Korean Society of Endocrinology||-|
|dc.identifier.bibliographicCitation||Journal of Korean Society of Endocrinology, 19(5):485-491, 2004||-|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.